Company Information
Industry 制造业
Company Introduction 诺诚健华(上交所代码:688428;港交所代码:09969)是一家商业化阶段的生物医药高科技公司,于2015年由拥有丰富新药研发及企业管理经验的崔霁松博士和世界著名结构生物学家施一公院士联合创立。我们为恶性肿瘤和自身免疫性疾病患者研发创新药,让创新成果惠及更多患者。 积累创新的价值,相信时间的力量。我们从一个个分子开始,向着人类健康蓝图迈进,持续开发创新技术与疗法,并构建完善的全球知识产权和质量管理体系。 我们构建起从源头创新、临床开发、生产到商业化的全产业链平台,致力于为全世界恶性肿瘤和自身免疫性疾病患者开发并提供创新疗法。我们在北京、南京、上海、广州、香港以及美国设有分支机构。
Main Business 肿瘤及自身免疫性疾病创新药的研发。
Legal Representative 崔霁松
Top Executives
执行董事:Jisong Cui(崔霁松),Renbin Zhao(赵仁滨)
非执行董事:施一公,谢榕刚
独立非执行董事:胡兰,董丹丹
Top 5 Shareholder
Shareholder name Nature Holding Date
HKSCC NOMINEES LIMITEDH股41.46%30/06/2024
HHLRFund,L.P.及其一致行动人H股11.84%30/06/2024
KingBridgeInvestmentsLimited及其一致行动人H股9.00%30/06/2024
SunnyViewHoldingsLimited与RenbinZhao(赵仁滨)家族H股8.20%30/06/2024
VivoCapitalFundVIII,L.P.及其一致行动人H股7.33%30/06/2024
Company Secretary --
Solicitors 上海市方达律师事务所
Auditors 天健会计师事务所(特殊普通合伙);安永华明会计师事务所(特殊普通合伙)
Tel No 0010-66609913
Fax No 0010-60702992
Website www.innocarepharma.com
Email info@innocarepharma.com
Company Address
Register: Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands
Office: 北京市昌平区中关村生命科学园生命园路8号院8号楼
Listing Date 21/09/2022
Shares Capital
Shares Capital: 1,762,567,202
Total A Share: 266,282,967
Listed A Share: 266,282,967
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 1,496,284,235
EPS(RMB)* ¥ -0.370
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 4.054
Market Capitalization(RMB) 3.408B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.